Document Type

Journal Article

Publication Title

Pharmacogenomics

Volume

23

Issue

12

First Page

695

Last Page

708

PubMed ID

35971864

Publisher

Future Science Group

School

School of Medical and Health Sciences

RAS ID

52041

Comments

Masmoudi, H. C., Afify, N., Alnaqbi, H., Alhalwachi, Z., Tay, G. K., & Alsafar, H. (2022). HLA pharmacogenetic markers of drug hypersensitivity from the perspective of the populations of the Greater Middle East. Pharmacogenomics, 23(12), 695-708. https://doi.org/10.2217/pgs-2022-0078

Abstract

Specific HLA associations with drug hypersensitivity may vary between geographic regions and ethnic groups. There are little to no data related to HLA-drug hypersensitivity on populations who reside in the Greater Middle East (GME), a vast region spanning from Morocco in the west to Pakistan in the east. In this review, the authors intended to summarize the significant HLA alleles associated with hypersensitive drug reactions induced by different drugs, as have been found in different populations, and to summarize the prevalence of these alleles in the specific and diverse populations of the GME. For example, HLA-B * 57:01 allele prevalence, associated with abacavir-induced hypersensitivity, ranges from 1 % to 3 %, and HLA-DPB1 * 03:01 prevalence, associated with aspirin-induced asthma, ranges from 10 % to 14 % in the GME population. Studying pharmacogenomic associations in the ethnic groups of the GME may allow the discovery of new associations, confirm ones found with a low evidence rate and enable cost-effectiveness analysis of allele screening before drug use.

DOI

10.2217/pgs-2022-0078

Creative Commons License

Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.

Share

 
COinS